Axxcess Wealth Management LLC Sells 467 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Axxcess Wealth Management LLC cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 19.0% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,995 shares of the medical research company’s stock after selling 467 shares during the period. Axxcess Wealth Management LLC’s holdings in Charles River Laboratories International were worth $426,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of CRL. Trustcore Financial Services LLC purchased a new position in shares of Charles River Laboratories International in the 1st quarter valued at $28,000. Trust Co. of Vermont purchased a new position in shares of Charles River Laboratories International in the 2nd quarter valued at $29,000. Covestor Ltd increased its holdings in shares of Charles River Laboratories International by 100.0% in the 1st quarter. Covestor Ltd now owns 174 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 87 shares during the period. First Horizon Advisors Inc. increased its holdings in shares of Charles River Laboratories International by 110.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 253 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 133 shares during the period. Finally, Sugarloaf Wealth Management LLC increased its holdings in shares of Charles River Laboratories International by 33.8% in the 2nd quarter. Sugarloaf Wealth Management LLC now owns 285 shares of the medical research company’s stock valued at $61,000 after acquiring an additional 72 shares during the period. 95.20% of the stock is owned by institutional investors.

Charles River Laboratories International Price Performance

CRL stock opened at $241.08 on Thursday. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.40 and a quick ratio of 1.14. The business has a 50 day simple moving average of $211.63 and a 200-day simple moving average of $219.06. The firm has a market capitalization of $12.27 billion, a PE ratio of 28.40, a price-to-earnings-growth ratio of 1.59 and a beta of 1.28. Charles River Laboratories International, Inc. has a 1 year low of $181.36 and a 1 year high of $385.11.

Insider Activity

In other news, EVP Shannon M. Parisotto sold 2,279 shares of the company’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $249.90, for a total value of $569,522.10. Following the completion of the sale, the executive vice president now directly owns 2,499 shares in the company, valued at $624,500.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CAO Michael Gunnar Knell sold 855 shares of the stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $248.59, for a total value of $212,544.45. Following the completion of the transaction, the chief accounting officer now directly owns 6,438 shares in the company, valued at $1,600,422.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Shannon M. Parisotto sold 2,279 shares of the stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $249.90, for a total value of $569,522.10. Following the completion of the transaction, the executive vice president now owns 2,499 shares of the company’s stock, valued at $624,500.10. The disclosure for this sale can be found here. Insiders sold 3,668 shares of company stock worth $897,603 over the last ninety days. Corporate insiders own 1.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Citigroup cut their price target on Charles River Laboratories International to $280.00 in a report on Tuesday, August 9th. Deutsche Bank Aktiengesellschaft cut their price target on Charles River Laboratories International from $290.00 to $270.00 in a report on Monday, August 8th. Wells Fargo & Company dropped their target price on Charles River Laboratories International from $325.00 to $300.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 16th. William Blair restated an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday, November 2nd. Finally, Evercore ISI dropped their target price on Charles River Laboratories International to $260.00 in a research note on Tuesday, August 9th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $298.42.

Charles River Laboratories International Profile

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Further Reading

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.